MOLOGEN AG confirmed its outlook for the 2015 financial year. In view of the progress made in ongoing study programs, a significant year-on-year increase in R&D expenses is still expected for the 2015 financial year. This will lead to a higher net loss for 2015.
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |